{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:14:57Z","timestamp":1762877697565,"version":"3.45.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04408-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:19:44Z","timestamp":1762874384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Awareness, attitudes, and clinical utilization of vonoprazan for Helicobacter pylori infection and gastroesophageal reflux disease among Chinese physicians: a nationwide cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heqing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"43","key":"4408_CR1","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.3748\/wjg.v30.i43.4636","volume":"30","author":"L Xie","year":"2024","unstructured":"Xie L, et al. Prevalence of Helicobacter pylori infection in China from 2014\u20132023: a systematic review and meta-analysis. World J Gastroenterol. 2024;30(43):4636\u201356.","journal-title":"World J Gastroenterol"},{"issue":"45","key":"4408_CR2","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.3748\/wjg.v28.i45.6410","volume":"28","author":"TL Lu","year":"2022","unstructured":"Lu TL, et al. Meta-analysis on the epidemiology of gastroesophageal reflux disease in China. World J Gastroenterol. 2022;28(45):6410\u201320.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4408_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bpg.2006.11.004","volume":"21","author":"P Moayyedi","year":"2007","unstructured":"Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):347\u201361.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"8","key":"4408_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-014-0164-8","volume":"32","author":"AJ Gawron","year":"2014","unstructured":"Gawron AJ, et al. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32(8):745\u201358.","journal-title":"Pharmacoeconomics"},{"key":"4408_CR5","doi-asserted-by":"crossref","unstructured":"Zhou L et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899\u20132910.","DOI":"10.1097\/CM9.0000000000002546"},{"issue":"2","key":"4408_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/agm2.12293","volume":"7","author":"L Fangxu","year":"2024","unstructured":"Fangxu L, et al. Chinese expert consensus on diagnosis and management of gastroesophageal reflux disease in the elderly (2023). Aging Med (Milton). 2024;7(2):143\u201357.","journal-title":"Aging Med (Milton)"},{"issue":"2","key":"4408_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2023.09.047","volume":"166","author":"SF Moss","year":"2024","unstructured":"Moss SF, et al. Evolving concepts in <\u2009em\u2009>\u2009Helicobacter pylori\u2009Management. Gastroenterology. 2024;166(2):267\u201383.","journal-title":"Gastroenterology"},{"key":"4408_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEG.S121056","volume":"11","author":"J Mermelstein","year":"2018","unstructured":"Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119\u201334.","journal-title":"Clin Exp Gastroenterol"},{"key":"4408_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618809927","volume":"10","author":"M Jaynes","year":"2019","unstructured":"Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019;10:2042098618809927.","journal-title":"Ther Adv Drug Saf"},{"issue":"11\u201312","key":"4408_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, et al. The binding selectivity of Vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42(11\u201312):1315\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4408_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11938-020-00330-x","volume":"19","author":"C Scarpignato","year":"2021","unstructured":"Scarpignato C, Hunt RH. Acid suppressant therapy: a step forward with Potassium-Competitive acid blockers. Curr Treat Options Gastroenterol. 2021;19(1):94\u2013132.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"2","key":"4408_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gande.2023.01.001","volume":"1","author":"Z Hu","year":"2023","unstructured":"Hu Z, et al. Chinese consensus on multidisciplinary diagnosis and treatment of gastroesophageal reflux disease 2022. Gastroenterol Endoscopy. 2023;1(2):33\u201386.","journal-title":"Gastroenterol Endoscopy"},{"key":"4408_CR13","volume":"82","author":"M Shehryar","year":"2022","unstructured":"Shehryar M, et al. Efficacy, safety and cost-effectiveness of Vonoprazan vs proton pump inhibitors in reflux disorders and H. pylori eradication: a literature review. Ann Med Surg (Lond). 2022;82:104760.","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"4408_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/s12913-021-07196-4","volume":"21","author":"K Medlinskiene","year":"2021","unstructured":"Medlinskiene K, et al. Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021;21(1):1198.","journal-title":"BMC Health Serv Res"},{"key":"4408_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.","journal-title":"BMC Health Serv Res"},{"issue":"5\u20136","key":"4408_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/1751-2980.13104","volume":"23","author":"YL Xiao","year":"2022","unstructured":"Xiao YL, et al. Patient- and physician-reported satisfaction with gastroesophageal reflux disease (GERD) treatment in Chinese clinical practice. J Dig Dis. 2022;23(5\u20136):262\u20139.","journal-title":"J Dig Dis"},{"issue":"12","key":"4408_CR17","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1007\/s10620-010-1209-2","volume":"55","author":"WD Chey","year":"2010","unstructured":"Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55(12):3415\u201322.","journal-title":"Dig Dis Sci"},{"issue":"26","key":"4408_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043058","volume":"104","author":"JM Liu","year":"2025","unstructured":"Liu JM, et al. Gastroenterologists\u2019 perspectives of high-dose dual therapy for Helicobacter pylori infection in China: results of a China survey. Medicine (Baltimore). 2025;104(26):e43058.","journal-title":"Medicine (Baltimore)"},{"key":"4408_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231168714","volume":"16","author":"CW Howden","year":"2023","unstructured":"Howden CW, et al. Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan. Ther Adv Gastroenterol. 2023;16:17562848231168714.","journal-title":"Ther Adv Gastroenterol"},{"issue":"17","key":"4408_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2169\/internalmedicine.0492-17","volume":"57","author":"R Niikura","year":"2018","unstructured":"Niikura R, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018;57(17):2443\u201350.","journal-title":"Intern Med"},{"issue":"5","key":"4408_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5009\/gnl250067","volume":"19","author":"JY Park","year":"2025","unstructured":"Park JY, et al. Comparative efficacy of potassium-competitive acid blocker-based triple therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori eradication: a randomized, double-blind, active-controlled pilot study. Gut Liver. 2025;19(5):696\u2013705.","journal-title":"Gut Liver"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vhri.2021.12.003","volume":"30","author":"GG Liu","year":"2022","unstructured":"Liu GG, et al. Policy updates on access to and affordability of innovative medicines in China. Value Health Reg Issues. 2022;30:59\u201366.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"4408_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-025-02390-w","volume":"24","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, et al. Impacts of national reimbursement drug price negotiation on drug accessibility, utilization, and cost in China: a systematic review. Int J Equity Health. 2025;24(1):36.","journal-title":"Int J Equity Health"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04408-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04408-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04408-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:19:47Z","timestamp":1762874387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04408-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04408-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was exempt from ethics approval by the Beijing You\u2019an Hospital Institutional Review Board because of the anonymous, non-interventional survey design. Informed consent was obtained electronically before survey completion. All procedures performed in studies involving human participants were conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"795"}}